Explored approaches to overcoming drug resistance in patients treated with HER2+ tumors involve the Wnt/β-catenin signaling pathway, which regulates epithelial-to-mesenchymal transition (EMT), promoting tumor invasion and metastasis, and contributing to drug resistance [18,19]. The gene discussed is ERBB2; the disease is neoplasm.